COR2ED Medical Education: Prof. Dr Amit Singal, Gastroenterologist and Hepatologist at UT Southwestern Medical Center, USA and Prof. Dr Jeroen Dekervel, GI Oncologist at UZ Leuven, Belgium, discuss the new era in treating patients with advanced HCC, focusing on treatment selection and the right time to switch to 2nd line therapy. In this podcast, the experts give an overview of the current 1st and 2nd line systemic treatment options and sequences for patients with advanced HCC by looking into the results from different clinical trials and current guidelines. They also shine a light on the differences in approved 2nd line systemic therapies between Europe and USA. The experts present their approach in making the decision to switch to 2nd line therapy, thereby taking toxicity, liver function and disease progression into account. They also discuss the need for comparative effectiveness data to determine the optimal 2nd line therapy.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related